Scenic’s co-founder Thijn Brummelkamp and advisor Ton Schumacher report identification of a PD-L1 modifier in Nature

A team of researchers at the Netherlands Cancer institute including Thijn Brummelkamp and Ton Schumacher have identified CMTM6 as a critical modifier of the immune checkpoint protein PD-L1. The work highlights CMTM6 as a potential new drug target to combat cancer.